Hugo A Barrera-Saldaña, Rafael B R León-Cachón, Vanessa González-Covarrubias, Héctor E Sánchez-Ibarra, Fernando Lavalle-González
{"title":"Contributions of pharmacogenetics to personalized precision therapy of diabetes and hypercholesterolemia.","authors":"Hugo A Barrera-Saldaña, Rafael B R León-Cachón, Vanessa González-Covarrubias, Héctor E Sánchez-Ibarra, Fernando Lavalle-González","doi":"10.24875/GMM.M25000975","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Personalized medicine allows the selection of the drug and dose based on the patient's genetic information, which is imperative in the treatment of diabetes and hypercholesterolemia, diseases with high prevalence in Mexico.</p><p><strong>Objective: </strong>To integrate pharmacogenetic and genomic research on antidiabetic and antihypercholesterolemic drugs in Mexican patients.</p><p><strong>Material and methods: </strong>We integrated our research, relating it with similar research from national and foreign laboratories.</p><p><strong>Results: </strong>For antidiabetic pharmacological treatments, variants in the ABCC8 and KCNJ11 genes were consistently associated with the response to sulfonylureas, while variants in the SLC47A1, SLC28A1 and ABCG2 genes explained up to 55% of the variability in the response to metformin. Regarding hypercholesterolemia, atorvastatin treatment is influenced by variants in the genes MTHFR, DRD3, GSTM3, TNFα MDR1, SLCO1BI, ABCB1, CYP2D6, CYP2B6, NAT2 and COMT.</p><p><strong>Conclusion: </strong>Our findings highlight the need to integrate pharmacogenetics into clinical practice to achieve greater therapeu tic success in diabetes and hypercholesterolemia.</p>","PeriodicalId":12736,"journal":{"name":"Gaceta medica de Mexico","volume":"161 1","pages":"94-101"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaceta medica de Mexico","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/GMM.M25000975","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Personalized medicine allows the selection of the drug and dose based on the patient's genetic information, which is imperative in the treatment of diabetes and hypercholesterolemia, diseases with high prevalence in Mexico.
Objective: To integrate pharmacogenetic and genomic research on antidiabetic and antihypercholesterolemic drugs in Mexican patients.
Material and methods: We integrated our research, relating it with similar research from national and foreign laboratories.
Results: For antidiabetic pharmacological treatments, variants in the ABCC8 and KCNJ11 genes were consistently associated with the response to sulfonylureas, while variants in the SLC47A1, SLC28A1 and ABCG2 genes explained up to 55% of the variability in the response to metformin. Regarding hypercholesterolemia, atorvastatin treatment is influenced by variants in the genes MTHFR, DRD3, GSTM3, TNFα MDR1, SLCO1BI, ABCB1, CYP2D6, CYP2B6, NAT2 and COMT.
Conclusion: Our findings highlight the need to integrate pharmacogenetics into clinical practice to achieve greater therapeu tic success in diabetes and hypercholesterolemia.
期刊介绍：
Gaceta Médica de México México is the official scientific journal of the Academia Nacional de Medicina de México, A.C. Its goal is to contribute to health professionals by publishing the most relevant progress both in research and clinical practice.
Gaceta Médica de México is a bimonthly peer reviewed journal, published both in paper and online in open access, both in Spanish and English. It has a brilliant editorial board formed by national and international experts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
